SL Science Submits FDA Orphan Drug Request for Glioblastoma
Biotechnology
Business Update
Merger:
Jun 15, 2026
Industry:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Show Chart?
Load external content from TradingView!
*You can change or withdraw your consent at any time in the footer under Cookies.
SL Science Holding Limited Submits Orphan Drug Designation Request for Glioblastoma Treatment
Taipei, Taiwan - SL Science Holding Limited (Nasdaq: SLBT), a company specializing in innovative cellular and gene therapies, has announced the formal submission of an Orphan Drug Designation (ODD) request to the U.S. Food and Drug Administration (FDA). The application seeks designation for its Gamma Delta T (GDT) cell therapy product, Vdelta2+ Gamma Delta T Cells, specifically for the treatment of glioblastoma multiforme (GBM).
... Read on — Members only
About SL Science Holding Ltd
SL Bio is a biomedical company focused on developing innovative cellular and gene therapies for cancer treatment and regenerative medicine. Leveraging proprietary technologies and strategic partnerships, the company is advancing next-generation immunotherapies and exosome-based products for both medical and consumer applications. SL Bio’s approach combines scientific expertise with a commitment to improving patient outcomes and addressing unmet needs in healthcare. SL Bio also offers ISO-certified, dermatologically tested cow milk-derived exosome-based products and plant extract products for skin and hair care, with commercial distribution in Asia.
